(NYSE: MRK) Merck & Co's forecast annual revenue growth rate of 4.2% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 7.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.69%.
Merck & Co's revenue in 2026 is $66,569,000,000.On average, 31 Wall Street analysts forecast MRK's revenue for 2026 to be $167,313,711,802,608, with the lowest MRK revenue forecast at $160,694,290,297,854, and the highest MRK revenue forecast at $174,858,322,671,612. On average, 31 Wall Street analysts forecast MRK's revenue for 2027 to be $175,238,267,103,864, with the lowest MRK revenue forecast at $165,127,797,731,340, and the highest MRK revenue forecast at $187,667,877,816,108.
In 2028, MRK is forecast to generate $186,478,701,086,592 in revenue, with the lowest revenue forecast at $166,830,146,161,560 and the highest revenue forecast at $207,891,283,732,794.